STOCK TITAN

Moleculin Biotech, Inc. - MBRX STOCK NEWS

Welcome to our dedicated page for Moleculin Biotech news (Ticker: MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotech stock.

Moleculin Biotech, Inc. (NASDAQ: MBRX) is a clinical stage pharmaceutical company focused on developing therapies for hard-to-treat tumors and viruses. Known for its innovative drug candidates, Moleculin's pipeline aims to address significant unmet medical needs. The company's flagship product, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance mechanisms and minimize cardiotoxicity. Annamycin is currently in Phase II clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Moleculin's research is rooted in discoveries from the acclaimed M.D. Anderson Cancer Center. In addition to Annamycin, the company is developing WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and other malignancies. WP1066 aims to inhibit oncogenic transcription factors such as p-STAT3 while stimulating the patient's immune response.

Another promising candidate, WP1220, an analog of WP1066, is being developed for the topical treatment of cutaneous T-cell lymphoma. The company also has a robust antimetabolite portfolio, including WP1122, which is being investigated for its potential in treating both viral infections and various cancers.

Recent achievements highlight Moleculin's significant progress. Positive preclinical data for Annamycin were presented at the American Association for Cancer Research (AACR) Annual Meeting, demonstrating its non-cardiotoxic properties and potent inhibition of topoisomerase II-beta. Annamycin has also received Orphan Drug Designation from both the FDA and the European Medicines Agency (EMA) for AML, providing Moleculin with extended market exclusivity and reduced regulatory fees.

Financially, Moleculin maintains a solid footing with sufficient capital to support its ongoing clinical trials and future projects. The company's recent financial report indicates a strategic focus on advancing its clinical and regulatory strategies. With multiple patents issued and pending, Moleculin continues to strengthen its intellectual property portfolio, positioning itself favorably for potential partnerships and market expansion.

Collaborations with leading institutions such as Northwestern University and funding from entities like the National Institutes of Health (NIH) underscore the robust support for Moleculin's initiatives. The company's innovative approach and commitment to addressing challenging medical conditions make it a noteworthy entity in the biopharmaceutical landscape.

For more details, please visit Moleculin's website and connect on Twitter, LinkedIn, and Facebook.

Rhea-AI Summary

Moleculin Biotech, Inc. (Nasdaq: MBRX) will host a virtual AML Clinical Day featuring Dr. Martin Tallman, discussing the unmet medical needs in AML treatment, Annamycin, and the Company's AML clinical development program. The event will highlight the ongoing progress of Annamycin towards a pivotal AML study in 2024 for potential accelerated approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
conferences
-
Rhea-AI Summary

Moleculin Biotech, Inc. announced the formation of its Annamycin Scientific Advisory Board, appointing Dr. Martin Tallman as the inaugural clinician member. Dr. Tallman, an internationally renowned clinician, brings extensive experience in leukemia-targeting therapies. The company aims to advance the development of Annamycin, a promising treatment for AML and STS lung mets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
management
-
Rhea-AI Summary
Moleculin Biotech (NASDAQ:MBRX) CEO, Walter Klemp, discusses the positive interim data from the ongoing clinical trial on Annamycin for Acute Myeloid Leukemia (AML) treatment in a Virtual Investor 'What This Means' segment hosted by JTC Team. The segment highlights Annamycin's differentiation in the current AML treatment landscape and the investment opportunity for Moleculin.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
Rhea-AI Summary
Moleculin Biotech, Inc. receives Orphan Drug Designation from the European Medicines Agency (EMA) for Annamycin, a next-generation anthracycline, for the treatment of Acute Myeloid Leukemia (AML). Annamycin shows promising clinical efficacy in AML with a preliminary complete response rate of 60% in 2nd line subjects in a European clinical trial. The drug demonstrates lower toxicity than traditional therapies and is advancing towards a pivotal AML study in 2024. The Orphan Drug Designation provides commercial exclusivity and regulatory benefits for Moleculin's innovative cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.7%
Tags
-
Rhea-AI Summary
Moleculin Biotech, Inc. announces positive preclinical data on Annamycin, a potent anthracycline with non-cardiotoxic properties, presented at AACR Annual Meeting. Annamycin shows high potency against topoisomerase II-alpha and II-beta, while remaining safe for cardiomyocytes. The company's recent patent issuance enables expansion into patient populations with unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
none
-
Rhea-AI Summary
Moleculin Biotech, Inc. (MBRX) to present at the MedInvest Biotech & Pharma Investor Conference on April 4th, 2024. The company's President and CEO, Walter Klemp, will discuss their drug candidates targeting tumors and viruses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.68%
Tags
conferences
Rhea-AI Summary
Moleculin Biotech, Inc. (MBRX) will present at the Virtual Investor Lunch Break, featuring Chairman and CEO Walter Klemp discussing the company's drug candidates targeting tumors and viruses. The event will take place on March 28th, with a live webcast available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.38%
Tags
conferences
-
Rhea-AI Summary
Moleculin Biotech, Inc. receives a patent for a next-generation anthracycline with composition of matter protection until 2040, showcasing promising results in treating AML patients and soft tissue sarcoma lung metastases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.38%
Tags
none
-
Rhea-AI Summary
Moleculin Biotech, Inc. announces positive results for Annamycin in combination with Cytarabine (AnnAraC) in 2nd line AML subjects, achieving a CRc rate of 60% with a potential to fill a significant unmet need. The company reports no signs of cardiotoxicity in all 82 Annamycin subjects and plans to advance towards a pivotal AML study in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.98%
Tags
Rhea-AI Summary
Moleculin Biotech, Inc. reports positive clinical data for Annamycin, plans pivotal study for AML. Financial results show increased R&D expenses but decreased G&A expenses. The company closed a direct offering and private placement, extending cash runway into Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.98%
Tags

FAQ

What is the current stock price of Moleculin Biotech (MBRX)?

The current stock price of Moleculin Biotech (MBRX) is $1.73 as of December 23, 2024.

What is the market cap of Moleculin Biotech (MBRX)?

The market cap of Moleculin Biotech (MBRX) is approximately 4.9M.

What is Moleculin Biotech's lead product candidate?

Moleculin's lead product candidate is Annamycin, a next-generation anthracycline designed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

What are the key focus areas of Moleculin Biotech's research?

Moleculin Biotech focuses on developing therapies for hard-to-treat tumors and viruses, including drug candidates like Annamycin for AML and STS, and WP1066 for brain tumors and pancreatic cancer.

What recent achievements has Moleculin Biotech reported?

Moleculin has presented positive preclinical data on Annamycin's non-cardiotoxic properties, received Orphan Drug Designation for AML from both the FDA and EMA, and secured new patents for Annamycin.

How is Moleculin Biotech financially positioned?

Moleculin maintains sufficient capital to support its ongoing Phase IIB/2 clinical programs and additional future projects, as indicated by its latest financial report.

What collaborations is Moleculin Biotech involved in?

Moleculin collaborates with top institutions like Northwestern University and receives funding from entities such as the National Institutes of Health (NIH).

What is the significance of Annamycin's Orphan Drug Designation?

Orphan Drug Designation grants Moleculin benefits like reduced regulatory fees and market exclusivity for Annamycin, supporting its development for rare conditions like AML.

What is WP1066, and what does it target?

WP1066 is an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and other malignancies. It aims to inhibit oncogenic transcription factors and stimulate the immune response.

What is WP1220 used for?

WP1220 is an analog of WP1066, being developed for the topical treatment of cutaneous T-cell lymphoma.

What is the potential of WP1122?

WP1122 is part of Moleculin's antimetabolite portfolio, currently being explored for treatment of viral infections and various cancers, including brain and pancreatic tumors.

Where can I find more information about Moleculin Biotech?

For more information, visit Moleculin's website at www.moleculin.com and follow them on social media platforms like Twitter, LinkedIn, and Facebook.

Moleculin Biotech, Inc.

Nasdaq:MBRX

MBRX Rankings

MBRX Stock Data

4.85M
3.09M
3.34%
15.34%
1.8%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
HOUSTON